President Obama Pushes BRAIN Initiative Forward
|
By LabMedica International staff writers Posted on 09 Apr 2013 |
In his State of the Union address, US President Obama outlined his strategy for creating jobs and building a growing, flourishing middle class by making an historic investment in medical research and development.
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
“If we want to make the best products, we also have to invest in the best ideas... Every dollar we invested to map the human genome returned USD 140 to our economy... Today, our scientists are mapping the human brain to unlock the answers to Alzheimer’s… Now is not the time to gut these job-creating investments in science and innovation. Now is the time to reach a level of research and development not seen since the height of the space race,” stated President Barack Obama, in the 2013 State of the Union address.
On April 2, 2012, at the White House, the President revealed an intrepid new research initiative designed to transform understanding of the human brain. Initiated with about USD 100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative’s goal to help researchers find new ways to treat, cure, and even prevent brain disorders, such as epilepsy, Alzheimer’s disease, and traumatic brain injury.
The BRAIN Initiative is designed to hasten the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will create new ways to examine how the brain records, processes, uses, stores, retrieves vast quantities of information, and provide insights into the complex ties between behavior and brain function.
This initiative is one of the Administration’s “Grand Challenges” goals that require new developments in science and technology. In his address, the President called on research universities, companies, research foundations, and philanthropists to join with him in identifying and pursuing the Grand Challenges of the 21st century.
The BRAIN Initiative includes: major investments to jumpstart the effort: The US National Institutes of Health (NIH; Bethesda, MD, USA), the Defense Advanced Research Projects Agency (DARPA; Arlington, VA, USA) , and the US National Science Foundation (Arlington, VA, USA) will support approximately USD 100 million in research beginning in FY 2014. Strong academic leadership: The NIH will establish a high-level working group cochaired by Dr. Cornelia Bargmann (The Rockefeller University; New York, NY, USA) and Dr. William Newsome (Stanford University; Stanford, CA, USA) to clarify detailed scientific goals for the NIH’s investment, and to develop a multiyear scientific plan for achieving these goals, including timetables, milestones, and cost estimates.
In the 10 years alone, scientists have made a number of landmark discoveries that now create the opportunity to gain further knowledge of the brain, including the sequencing of the human genome, the increasing resolution of imaging technologies, the development of new tools for mapping neuronal connections, and the expansion of nanoscience. These innovations have offered a chance for unprecedented collaboration and discovery across scientific fields. For instance, by combining sophisticated genetic and optical technologies, scientists can now use pulses of light to determine how specific cell activities in the brain affect behavior. Moreover, through the integration of neuroscience and physics, researchers can now use high-resolution imaging technologies to observe how the brain is structurally and functionally connected in living humans.
Whereas these technologic contributions have substantially added to expanding knowledge of the brain, significant breakthroughs in how physicians treat neurologic and psychiatric disease will require a new generation of applications to enable researchers to map signals from brain cells in much greater numbers and at even faster speeds. This cannot presently be accomplished, but great potential for developing such technologies lies at the crossroads of imaging, nanoscience, engineering, informatics, and other rapidly budding fields of science and engineering.
Related Links:
US National Institutes of Health
US Defense Advanced Research Projects Agency
US National Science Foundation
Latest BioResearch News
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
- Study Links Abnormal Gene Splicing to Treatment Response in Metastatic Kidney Cancer
- Research Reveals How Some Aplastic Anemia Patients Recover Bone Marrow Function
- New Molecular Insights Support Diagnosis of Hodgkin Lymphoma
- Epigenetic Signals and Blood Markers Aid Chronic Fatigue Syndrome Diagnosis
- Microenvironment Biomarkers Could Enable Early Lung Cancer Detection
- Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
- Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
- Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
- Single-Cell Method Measures RNA and Proteins to Reveal Immune Responses
- Study Links Midlife Vitamin D to Lower Tau in Alzheimer's
- International Consensus Standardizes Tumor Microbiota Detection and Reporting
- Common Metablolic Enzyme Could Predict Response to Cancer Immunotherapy
- Newly Identfied Genetic Variants in MND Support Prognosis and Family Testing
- Innate Immunity Variants Associated With Earlier Breast Cancer in BRCA1 Carriers
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring
Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel
Roche’s $1.05 Billion PathAI Acquisition Expands Digital Pathology Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








